Promomed Group received the award "For a high-tech project" from RSPP
Promomed 17 June 2024
Promomed Group, a leading innovative biopharmaceutical company, won the nomination "For a high-tech project" at the All-Russian competition of the Russian Union of Industrialists and Entrepreneurs (RSPP) "Flagships of Business: dynamics, responsibility, sustainability." The award was presented to the company by Alexander Shokhin, head of the RSPP.
In the "High-tech project" nomination, the Group presented the innovative biotechnological drug Radamin® Viro, developed by Promomed using its own RNA platform. This biotechnological platform is currently being developed by the corporate pharmaceutical clusters in Saransk and Moscow.
Radamin® Vira is used for the treatment and prevention of infectious and inflammatory diseases in adults and children. The drug is a potent inducer of three types of interferons, which ensures its high activity against viruses and bacteria and a pronounced anti-inflammatory effect.
"We are grateful to the RSPP for this prestigious award and the high appreciation of our team's work. When developing drug products, Promomed Group is guided by the principles that combine the introduction of innovations and high technologies. Radamin® Viro is one of the most remarkable examples of this approach. We are sure that meeting the needs of the country's population in advanced biopharmaceuticals of a new generation is an important function of a socially oriented pharmaceutical manufacturer; it forms the national drug independence," commented Kira Zaslavskaya, Director of New Products at Promomed Group.
The Russian national competition “Flagships of Business” is held annually and bring together companies from all business sectors. Its main purpose is to promote sustainable business development, which is in line with Russia’s long-term economic interests, and to find fast developing companies.
In the "High-tech project" nomination, the Group presented the innovative biotechnological drug Radamin® Viro, developed by Promomed using its own RNA platform. This biotechnological platform is currently being developed by the corporate pharmaceutical clusters in Saransk and Moscow.
Radamin® Vira is used for the treatment and prevention of infectious and inflammatory diseases in adults and children. The drug is a potent inducer of three types of interferons, which ensures its high activity against viruses and bacteria and a pronounced anti-inflammatory effect.
"We are grateful to the RSPP for this prestigious award and the high appreciation of our team's work. When developing drug products, Promomed Group is guided by the principles that combine the introduction of innovations and high technologies. Radamin® Viro is one of the most remarkable examples of this approach. We are sure that meeting the needs of the country's population in advanced biopharmaceuticals of a new generation is an important function of a socially oriented pharmaceutical manufacturer; it forms the national drug independence," commented Kira Zaslavskaya, Director of New Products at Promomed Group.
The Russian national competition “Flagships of Business” is held annually and bring together companies from all business sectors. Its main purpose is to promote sustainable business development, which is in line with Russia’s long-term economic interests, and to find fast developing companies.
